US2430094A - Isoxazole derivatives of - Google Patents
Isoxazole derivatives of Download PDFInfo
- Publication number
- US2430094A US2430094A US2430094DA US2430094A US 2430094 A US2430094 A US 2430094A US 2430094D A US2430094D A US 2430094DA US 2430094 A US2430094 A US 2430094A
- Authority
- US
- United States
- Prior art keywords
- isoxazole
- parts
- dimethyl
- amino
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000002545 isoxazoles Chemical class 0.000 title description 2
- 239000000243 solution Substances 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 16
- -1 sulfanilamide radical Chemical group 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical class NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 8
- 229940124530 sulfonamide Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- AKUSZFPCJFNRSZ-UHFFFAOYSA-N 3,4-dimethyl-1,2-oxazole Chemical compound CC1=CON=C1C AKUSZFPCJFNRSZ-UHFFFAOYSA-N 0.000 description 3
- GRDXCFKBQWDAJH-UHFFFAOYSA-N 4-acetamidobenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1 GRDXCFKBQWDAJH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PYNDWPFZDQONDV-UHFFFAOYSA-N 3,4-dimethyl-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1C PYNDWPFZDQONDV-UHFFFAOYSA-N 0.000 description 2
- UUFNWSJNIUWJEU-UHFFFAOYSA-N 3-(ethoxymethyl)-4-methyl-1,2-oxazol-5-amine Chemical compound CCOCC1=NOC(N)=C1C UUFNWSJNIUWJEU-UHFFFAOYSA-N 0.000 description 2
- HJYRCAWKSHTCHM-UHFFFAOYSA-N 4-ethoxy-2-methyl-3-oxobutanenitrile Chemical compound C(C)OCC(=O)C(C#N)C HJYRCAWKSHTCHM-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 229940083608 sodium hydroxide Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- IAXWZYXUKABJAN-UHFFFAOYSA-N 1,2-oxazol-5-amine Chemical class NC1=CC=NO1 IAXWZYXUKABJAN-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical group [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VNFHWCDNQQLEBI-UHFFFAOYSA-N 2-acetyl-4-aminobenzenesulfonamide Chemical compound CC(=O)C1=CC(N)=CC=C1S(N)(=O)=O VNFHWCDNQQLEBI-UHFFFAOYSA-N 0.000 description 1
- SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 description 1
- AIUXKRKSWAIROS-UHFFFAOYSA-N 3-amino-n-(1,2-oxazol-3-yl)benzenesulfonamide Chemical class NC1=CC=CC(S(=O)(=O)NC2=NOC=C2)=C1 AIUXKRKSWAIROS-UHFFFAOYSA-N 0.000 description 1
- CUMCMYMKECWGHO-UHFFFAOYSA-N 3-methyl-1,2-oxazole Chemical compound CC=1C=CON=1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- KBLGZYOVYFTAOB-UHFFFAOYSA-N 4-amino-n-(3-methyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound O1N=C(C)C=C1NS(=O)(=O)C1=CC=C(N)C=C1 KBLGZYOVYFTAOB-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- CSGGCKACDRUSMW-UHFFFAOYSA-N n-[3-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(S(=O)(=O)NC2=C(C(C)=NO2)C)=C1 CSGGCKACDRUSMW-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 150000003388 sodium compounds Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
Definitions
- sulfa drugs Another disadvantage of the sulfa drugs is their insolubility or. very slight solubility "in aqueous solutions at the pH of the body fluids, especially of urine with pH 5.5-7.
- Their precipitation in the kidneys in form of crystals causes much trouble and can lead to the most severe consequences; the medicalliterature quotes many cases of renal calculus formation, impairment of urinary excretion, fatal toxemia and uremia.
- one sulfanilyl derivative of 5-amino-isoxazole is k n o w n, namely, 5-sulfanilamido-3- methyl-isoxazole.
- This compound was first described by Backer and de Jonge (Rec. Tav. Chim. 61, 465, 1942) without any details on its chemotherapeutic activity. Later, Anderson, Faith, Marson, Winnek and Roblln (J. A. C. S. 64, 2903, 1942) synthesized the same compound and found some degree of bacteriostatic activity, but very little effect on experimental animal infections. Experiments made in our laboratories have confirmed these negative results.
- an alkoxy-substituted lower alkyl group such as methoxy-, ethoxy-, propyoxy-, methyl, ethyl; propyl;:- isopropyl, butyl, isobutyl or tertiary butyl radical with p-acetyl amino benzene sulfonylchloride and splitting of: the acetyl group from the thus obtained acetamino-benzene-sulfonylamino-isoxazole derivative, by a saponification process.
- p-acetylamino benzene sulfonylchloride instead of p-acetylamino benzene sulfonylchloride; p-nitrobenzene-sulfonylchloride can be used forthe condensation; in this case the result ing' nitro compounds have to be reduced to the corresponding amino compounds in the usual way.
- the water-soluble salts of our new compounds to which we have referred above and which have a neutral or nearly neutral reaction are those se-- lected from the group consisting of the alkali metal. alkaline-earth metal and strong organic base salts. Sodium hydroxide, carbonate orbicarbonate can be used to form the sodium salt,
- Ampul solutions for injections can easily be obtained from the alkali metal salts of our new compounds having a pH from 7.2-7.4; these solutions are stable and can be sterilized by boiling or autoclaving'without decomposition. They do not show 30 'sulfa drugs or their acetyl derivatives depend-on the solubility in urine at diflerent pH. .fi-illlsan and 'Plummer have shown these solubilitieszfor 3 sulfa drugs with the pyrimidine nucleus (sul'fadiazine, 'sulfamerazine and sulfamethazine, Proc.
- 1o saponifyins reagents can be used.
- the 3,4- dimethyl-5-amino-isoxazole used as a starting material' is preparedby reacting acetoproplonitrile with a hydroylamine salt under simultaneous neutralization of the acid, liberated during the reaction in hot aqueous, not too diluted, solution. It. crystallizes in beautiful white prisms from water and showsa M. P. of
- Example 2 224 parts 5-amino-3A-dimethyl-isoxazole are dissolved in a mixture of vol. parts pyridine plus 160 vol. parts acetone and 370 parts p-nitrobenzene-.S-sulfonylchloride are gradually added under cooling. After having stood at room temperature for 10 hours water is added. An oil is precipitated "which soon solidifies by crystallization. The crystals are sucked of! and washed .withfw t r.
- Example 3 v 126 part of 3-ethyl-4-methyl-5-amino-isoxazole-(J. Pract. Chem. 47, 128 (1893)) are converted to Sm-aoetamino-bemene-sulfonyl-am- 0 ino-3-ethyl-4-methylI isoxazole in analogy to Example 1.
- the compound forms white prisms of the M. P. 169".
- the saponification may be carried out with 18% hydrochloric acid or 3.
- N-sodiumhydroxide solution in analogy to Example 1. It furnishes the fi-sulfanilamido-3-ethyl-4-methyl-isoxazole whichmelts at 127.
- the 3-ethoxymethyl-4-methyl-5-amino isoxazole can be prepared in the following way: A mixture of 70 parts ethoxyethylacetate and 35 parts propionitrile are gradually added to a suspension of 11 parts sodium in 100 vol. parts benzene or ether. lution under evolution of hydrogen. The vessel is cooled with ice-water from the outside and a reflux condenser is used on .the top of the vessel. The reaction is usually terminated after -6 hours when all sodium has dissolved.
- Example 5 In a similar way, the lithium salt of 5- (p-aminobenzene-sulfonyl) -amino-3,4-dimethyl isoxazole The sodium gradually goes in sothan in water.
- Example 7 If the sodium salt of Example 5 is dissolved in water and the aqueous solution shaken with an excess of 5-sulfanilamido-3,4-diamethyl-lsox- 2.2016, the pH of the solution changes from a little above pH 8 to pH 7.2. The solution is filtered and can be sterilized at 100 without changing'the properties.
- a solution of the lithium salt of pH 7.2 to 7.4 can be prepared.
- Stable solutions which contain 20% or more of the sulfanilamide can also beprepared.
- Similar solutions with a. pH varying from 7-7.5 can be obtained from the preparations of Examples 3 and 4.
- Example 8 If an aqueous suspension of 5-sulfanilamido- .3,4-dimethyl-isoxazole is heated with an excess of calcium carbonate and then filtered, a stable solution containing the calcium salt o1?v the sulfanilamide is obtained. It has similar properties of Example 7 solutions. Instead of the calcium carbonate, magnesium carbonate gives a stable solution containing the magnesium salt of the sulfanilamide. Similar solutions are obainable from the preparations of Examples 3 and 4.
- Example 9 If an aqueous suspension of 5-sulfanilamido- 3,4-dimethyl isoxazole is treated with diethanolamine to a pH of 7.2 to 7.4, the compound dissolves and furnishes a stable solution containing the diethanolamine salt of the sulfanilamide. High concentrated stable solutions of the sulfanilamide showing a pH of 7.2 to 7.4 thus can be prepared. Similar solutions result if, instead of diethanolamine, other organic bases such as ethanolamine, ethylenediamine are used.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Patented Nov. 4, 1947 ISOXAZOLE DERIVATIVES OF SULFANILAMIDE Heinz M. Wuest, Upper Montclair, and Max Hoffer, Nutley, N. .L,
asslgnors to Hofimann-La Roche, Inc., Nutley, N. J., a corporation of New Jersey No Drawing. Application July 11, 1944, Serial No. 544,342
Claims. (Cl. 260-2395) Our invention relates to new'isoxazole derivatives, and to processes for manufacturing them. These derivatives are the 5-sulfanilamido-isoxazoles of the general formula wherein R and R are lower alkyl and/or lower alkoxy alkyl groups.
As is well known, hundreds of sulfanilamides have been synthesized, investigated and described in th literature. Only a few of them have their well established place intherapy and all hitherto known sulfa drugs have marked disadvantages.
One disadvantage of these known sulfanilamides is that they are weak acids and form sodium salts which in aqueous solution react strongly alkaline, having pH ranges from 9-11 (New and Nonoflicial Remedies 1943, p. 187; Feinstone et al., C. A. 1941 1509; Ellingson, J. A. C. S. 1941, 2524). The strongly alkaline solutions cannot be sterilized by boiling or autoclaving as they are unstable under such conditions (see N. N. R. 1943, p. 187/189). They can only be injected intravenously and not intramuscularly, as they are highly irritating to the tissues; even on intravenous injection they tend to produce thrombosis of the veins.
Another disadvantage of the sulfa drugs is their insolubility or. very slight solubility "in aqueous solutions at the pH of the body fluids, especially of urine with pH 5.5-7. Their precipitation in the kidneys in form of crystals (consisting of the sulfa drugs themselves or their N -acetyl derivatives) causes much trouble and can lead to the most severe consequences; the medicalliterature quotes many cases of renal calculus formation, impairment of urinary excretion, fatal toxemia and uremia.
With the object in view of overcoming these serious disadvantages of known sulfa compounds, we have made the surprising discovery that the compounds illustrated by the general formula shown. above in which a disubstituted isoxazole ring is attached to the N -position of sulfanila- .mide possess relatively high acidity which is strong enough to enable these compounds to form water-soluble salts with bases, which salts possess neutral or nearly neutral reaction. Owing to this outstanding physico-chemical property and in contrast to all known sulfa compounds, the salts are therapeutical agents of greatly improved characteristics and can be injected without irritation, as we shall demonstrate further below.
Sulfanilamide derivatives with the isoxazole ring attached in 'N p0siti0n of the sulfanilamide molecule have already been described in literature. These compounds are different from those of the present invention, as they are substituted by the sulfanilamide radical in 4-position of the isoxazole ring; nothing has been reported on their chemotherapeutic properties or their therapeutic value. (Carlo Musante, Gazz. Chim. Ital. 71, 565, 1941.)
Also, one sulfanilyl derivative of 5-amino-isoxazole is k n o w n, namely, 5-sulfanilamido-3- methyl-isoxazole. This compound was first described by Backer and de Jonge (Rec. Tav. Chim. 61, 465, 1942) without any details on its chemotherapeutic activity. Later, Anderson, Faith, Marson, Winnek and Roblln (J. A. C. S. 64, 2903, 1942) synthesized the same compound and found some degree of bacteriostatic activity, but very little effect on experimental animal infections. Experiments made in our laboratories have confirmed these negative results.
We have discovered that the picture changes completely when both the 3- and 4- positions of the isoxazole ring of these sulfanilamide derivatives are replaced by an alkyl and/or corresponding alkoxy alkyl radical so that compounds of the above mentioned structural formula are obtained. These disubstituted derivatives have exhibited a high activity against experimental animal infections. Broad series of experiments have shown that their curative eflect on mice infected with hemolytic streptococci, pneumococci type 1, 2 and 3, meningococci and staphylococci is comparable to thebest sulfa drugs and surpasses them in some cases, especially with respect to meningococci andv pneumococci. Their acute and chronic toxicity is very low; daily injections in rabbits with 1.0 g./kg. for four weeks and chronic feeding of rats with normal diet containing 2% of 5- sulfanilamido-Zi, 4-d i m e t h y l-isoxazole for 8 wherein R and R stand for a lower alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl. isobutyl and tart. butyl. and/or an alkoxy-substituted lower alkyl group such as methoxy-, ethoxy-, propyoxy-, methyl, ethyl; propyl;:- isopropyl, butyl, isobutyl or tertiary butyl radical with p-acetyl amino benzene sulfonylchloride and splitting of: the acetyl group from the thus obtained acetamino-benzene-sulfonylamino-isoxazole derivative, by a saponification process.
Instead of p-acetylamino benzene sulfonylchloride;p-nitrobenzene-sulfonylchloride can be used forthe condensation; in this case the result ing' nitro compounds have to be reduced to the corresponding amino compounds in the usual way.
The water-soluble salts of our new compounds to which we have referred above and which have a neutral or nearly neutral reaction are those se-- lected from the group consisting of the alkali metal. alkaline-earth metal and strong organic base salts. Sodium hydroxide, carbonate orbicarbonate can be used to form the sodium salt,
and the free compounds can be titrated as monobasic acids with n-alkali in 50% alcohol. Ampul solutions for injections can easily be obtained from the alkali metal salts of our new compounds having a pH from 7.2-7.4; these solutions are stable and can be sterilized by boiling or autoclaving'without decomposition. They do not show 30 'sulfa drugs or their acetyl derivatives depend-on the solubility in urine at diflerent pH. .fi-illlsan and 'Plummer have shown these solubilitieszfor 3 sulfa drugs with the pyrimidine nucleus (sul'fadiazine, 'sulfamerazine and sulfamethazine, Proc. Soc. Exp. Biol. Med. 53.142, 1943). It is obvious that only the solubilities at pH under 7 are relevantas-urine isin most cases acid.. We have determined the solubility of a characteristic member of our new compounds at various pH and compared with the'curves of Gilligan and Plummer. The superiority of 5-sulfanilamido-'3,4-dimethyl-isoxazole over the pyrimidine compounds is exhibited in a, very drastic manner: the solubilit at H5-7 issohi hthat ithe th comy p g M r e 60. 200 volnp'arts water and 100 parts crystallizedpound itself nor its acetyl derivative will be deposited in the kidneys.
The following examples illustrate our invn:
7 tion:
Example 1 112. parts of 3,4-dimethyl-5-amino-isoxazole were dissolved in a mixture of 100 vol. parts of pyridine and '100 vol. parts of acetone. The mixture is cooled with cold water and 240 parts pacetamino-benzene sultonic acid chloride are added in small portions under stirring at temperatures of below 30. The mixture is left standing --overnight at -30 and then the B-acetaminobenzene-sulfonylamino-3,4-dimethyl-isoxazole is precipitated by the addition of water, Recrystalequ. w.=309; found: C=50.33, H=4.87, N=13.22
equ. w. =309.
100 parts of the 5-acetamino-benzene-sulfonyl amino-3,4-dimethyl-isoxazole are boiled under reflux with 500 vol. parts 15-20% aqueous hydrochloric acid for -45 minutes until all is dissolved.-
500 parts crystallized sodium acetate are added isoxazole are converted to.
, 1o saponifyins reagents can be used.
. 4 and the liquid left cooling for crystallization. The sulfanllamido-3,4-dimethyl-isoxazole is sucked off. washed with water and dried. In the pure stat; it forms white prisms with the melting-point 3 i 5 Analysis: Calcd. for. CuHuNaOJS': C=-i9.4, 8:430, N=l5.7, equiv.-w.=287; found: C=49.54, H=5.00, N=l5.72. equiv. w.=26l.
Also, instead of the hydrochloric acid alkaline parts of acetamino-benzene-sulfonyl-amino-3,4-dimethylisoxazole are heatedmith 500 vol. parts 3N-so dium hydroxide solution on a steam bath for one hour. The solution furnished the 5-sulfanil- 5 amide-3,4-dimethyl-is'oxazole when acidified with acetic acid in very good yield;
The 3,4- dimethyl-5-amino-isoxazole used as a starting material'is preparedby reacting acetoproplonitrile with a hydroylamine salt under simultaneous neutralization of the acid, liberated during the reaction in hot aqueous, not too diluted, solution. It. crystallizes in beautiful white prisms from water and showsa M. P. of
Example 2 224 parts 5-amino-3A-dimethyl-isoxazole are dissolved in a mixture of vol. parts pyridine plus 160 vol. parts acetone and 370 parts p-nitrobenzene-.S-sulfonylchloride are gradually added under cooling. After having stood at room temperature for 10 hours water is added. An oil is precipitated "which soon solidifies by crystallization. The crystals are sucked of! and washed .withfw t r. .1- '1"he crude p-nitrobenzene-5-sul- '4 dimethyl isoxazole contains benzene-sulfonyl-amino-dimeth- .1207") and can be separated to its solubility in alkali. The obenz'enesulfonyl amino dimethyl and meltsf'at-ld'i".
0 isoxazoleieanb cry'stallized'from diluted alcohol dimethyljisoxazole are suspended in 200 vol. parts alcoholga'nd .l5otvolgparts concentrated hydro- 45 chlori'c acid and heated to 6040". 40 parts zinc dust are gradually added under stirring. When the vigorous reaction has ceased the mixture is still keptboiling under reflux: for, 30 minute and then filtered from some undlssolved zinc dust.
Example 3 v 126 part of 3-ethyl-4-methyl-5-amino-isoxazole-(J. Pract. Chem. 47, 128 (1893)) are converted to Sm-aoetamino-bemene-sulfonyl-am- 0 ino-3-ethyl-4-methylI isoxazole in analogy to Example 1. The compound forms white prisms of the M. P. 169".
Analysis: Calcd. for C14H11N3O4S:C=52.0, H=5.3, N=13.0; found: C=52.l9, H=5.45.
The saponificationmay be carried out with 18% hydrochloric acid or 3. N-sodiumhydroxide solution in analogy to Example 1. It furnishes the fi-sulfanilamido-3-ethyl-4-methyl-isoxazole whichmelts at 127.
70 Analysis? Calcd. for C12H15N30zS:C=51.2,
n=5.43, N=14.95; found: c=51.2a, 11:5.42.
. Etamble 4. [156 parts .,3-ethoxymethyl-4-methyl-5-aminoj- 40 partso'fthe p}nltrobenzen'e-sulfonyl-aminothe corresponding acetyl-sulfanilamid with 240 parts p-acetaminobenzene-sulfonic acid chloride in pyridine, acetone and the latter is saponified in analogy to: Example 1. The 5 sulfanilamino 3 ethoxymethyl-4-methyl-isoxazole thus obtained has a M. P. of 127. 7
Analysis: Calcd. for C1aH1'zO4NaS:C=50.2, H=5.46, N=13'.5; found: :49.95, H=5.27.
The 3-ethoxymethyl-4-methyl-5-amino isoxazole can be prepared in the following way: A mixture of 70 parts ethoxyethylacetate and 35 parts propionitrile are gradually added to a suspension of 11 parts sodium in 100 vol. parts benzene or ether. lution under evolution of hydrogen. The vessel is cooled with ice-water from the outside and a reflux condenser is used on .the top of the vessel. The reaction is usually terminated after -6 hours when all sodium has dissolved.
fully added, shaken, and the aqueous layer re-- moved. It contains the sodium compound of ethoxyacetyl-propionitrile formed according to the equation:
The solution is acidified with acetic acid, the oil which separates is taken up in ether, the ether layer is Washed with water and the ether is then distilled 01f, finally'in a vacuum. The residue forms a slight brown oil and is pure enough for' the formation of the 3-ethoxymethyl-4-methyl- 5-amino-isoxazole according to the equation:
30 parts of the crude ethoxyacetyl-propionitrile are heated with 18 parts hydroxylamine-hydrochloride in a mixture of 20 vol. parts alcohol and 5 vol, parts water under addition of 25 parts potassium acetate for 30 minutes at 80 under reflux, The reaction mixture is left to cool off and. then extracted with ethyl acetate. The extract is dried over sodium sulfate and the ethylacetate I distilled oil. The residue crystallizes after cooling and can be recrystallized from water. The 3 ethoxymethyl 4 methyl-S-amino isoxazole thus obtained forms white prisms or plates and melts at 69-70.
Analysis: Calcd. for C7H12O2Nz:C=53.8, H=7.7, N=l7.95; found: 0:53.98, H=7.61.
Example 5 In a similar way, the lithium salt of 5- (p-aminobenzene-sulfonyl) -amino-3,4-dimethyl isoxazole The sodium gradually goes in sothan in water.
which contain four 'mol water of crystallization Water is carecan be prepared. It dissolves even at 0 to more It crystallizes in large prisms and its solubility in water is over 20% at ll-5.
Example 7 If the sodium salt of Example 5 is dissolved in water and the aqueous solution shaken with an excess of 5-sulfanilamido-3,4-diamethyl-lsox- 2.2016, the pH of the solution changes from a little above pH 8 to pH 7.2. The solution is filtered and can be sterilized at 100 without changing'the properties.
In a similar way, a solution of the lithium salt of pH 7.2 to 7.4 can be prepared. Stable solutions which contain 20% or more of the sulfanilamide can also beprepared. Similar solutions with a. pH varying from 7-7.5 can be obtained from the preparations of Examples 3 and 4.
Example 8 If an aqueous suspension of 5-sulfanilamido- .3,4-dimethyl-isoxazole is heated with an excess of calcium carbonate and then filtered, a stable solution containing the calcium salt o1?v the sulfanilamide is obtained. It has similar properties of Example 7 solutions. Instead of the calcium carbonate, magnesium carbonate gives a stable solution containing the magnesium salt of the sulfanilamide. Similar solutions are obainable from the preparations of Examples 3 and 4.
Example 9 If an aqueous suspension of 5-sulfanilamido- 3,4-dimethyl isoxazole is treated with diethanolamine to a pH of 7.2 to 7.4, the compound dissolves and furnishes a stable solution containing the diethanolamine salt of the sulfanilamide. High concentrated stable solutions of the sulfanilamide showing a pH of 7.2 to 7.4 thus can be prepared. Similar solutions result if, instead of diethanolamine, other organic bases such as ethanolamine, ethylenediamine are used.
If instead of the 5-'sulfanilamido-3,4-dimethyl isoxazole the sulfanilamides from Examples 3 and 4 are used, solutions of the respective sulfanilamides showing analogy to the properties of the 5-sulfanilamido-3,4-dimethyl isoxazole are obtained.
What we claim is:
1. A compound selected from the group consisting of 5-sulfanilamido-3,4-dimethyleisoxazole, 5- sulfanilamido-3-oxymethy1-4 methyl isoxazole, and 5-sulfanilamldo-3-ethyl-4-methyl isoxazole, and alkali metal salts thereof.
' 2. A compound of the class consisting of 5-sulfanilamido-3,4-dimethyl-isoxazole of the formula CH3 CH3 4 3 NH SOs-NH-CS and alkali metal salts thereof.
4. The sodium salt of 5-sulfanliamido-3,4-dimethyl-isoxazole.
' 5. The lithium saitof 5-su1tan11amido-3A-di- Number Name j Date methyl-isoxazole. ,362,087 Newberry Nov. 7, 1944 mmz M. WUEST. 2,362,?36 Anderson Nov. 7. 1944 I a FOREIGN PA'I'ENTS REFERENCES CITED 1 Number Country Date 1 111,230 Australia Aug. 22 1940 The following references are of record in the A me of this patent: i 114,894 Australia Apr. 2,1942
UNITED STATES PATENTS OTHER REFERENCES Chemical Reviews, Aug, 1940. Pp. 105-109. Number Name Date JournaiAmer. Chem. Soc.. vol. 64, pp. 2902- 2,3 24,013 Moore July 13, 1943 2905 (Dec. 1942).
2.381. Hamilton Oct. 31, 1944 Chem.Abstracts,v0l.38,page232'1.
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2430094A true US2430094A (en) | 1947-11-04 |
Family
ID=3435681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US2430094D Expired - Lifetime US2430094A (en) | Isoxazole derivatives of |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2430094A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2555614A (en) * | 1949-03-11 | 1951-06-05 | Hoffmann La Roche | Derivatives of 5-(amino-phenylsulfonamido)-isoxazoles |
| US2721200A (en) * | 1953-07-13 | 1955-10-18 | Hoffmann La Roche | Sulfisoxazole compounds |
| US2809966A (en) * | 1957-10-15 | Aminobenzene-sulphoiyyl-z-amino- | ||
| US2881160A (en) * | 1955-11-30 | 1959-04-07 | Hoffmann La Roche | Bis-isoxazolyl-azobenzene-derivatives |
| US2888455A (en) * | 1956-09-04 | 1959-05-26 | Shionogi & Co | New sulfonamide and process for producing the same |
| US3468900A (en) * | 1966-08-24 | 1969-09-23 | Hoffman Lab Inc | Process for preparing isoxazole compounds |
| US3482957A (en) * | 1965-11-26 | 1969-12-09 | Toyo Kotsu Ind Inc | Method for suppressing the nitrification of ammonium nitrogen in soil and composition therefor |
| US3996356A (en) * | 1969-07-02 | 1976-12-07 | Hoffmann-La Roche Inc. | Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2324013A (en) * | 1941-07-31 | 1943-07-13 | Sharp & Dohme Inc | Amino-substituents of sulphanil-amide derivatives |
| US2361624A (en) * | 1941-09-20 | 1944-10-31 | Frederick M Turnbull | Stabilized therapeutic agents |
| US2362087A (en) * | 1938-06-03 | 1944-11-07 | May & Baker Ltd | Sulphanilamido-thiazoles |
| US2362336A (en) * | 1942-07-31 | 1944-11-07 | American Cyanamid Co | Sulphonamide derivatives of 2-aminooxazole and processes for their production |
-
0
- US US2430094D patent/US2430094A/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2362087A (en) * | 1938-06-03 | 1944-11-07 | May & Baker Ltd | Sulphanilamido-thiazoles |
| US2324013A (en) * | 1941-07-31 | 1943-07-13 | Sharp & Dohme Inc | Amino-substituents of sulphanil-amide derivatives |
| US2361624A (en) * | 1941-09-20 | 1944-10-31 | Frederick M Turnbull | Stabilized therapeutic agents |
| US2362336A (en) * | 1942-07-31 | 1944-11-07 | American Cyanamid Co | Sulphonamide derivatives of 2-aminooxazole and processes for their production |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809966A (en) * | 1957-10-15 | Aminobenzene-sulphoiyyl-z-amino- | ||
| US2555614A (en) * | 1949-03-11 | 1951-06-05 | Hoffmann La Roche | Derivatives of 5-(amino-phenylsulfonamido)-isoxazoles |
| US2721200A (en) * | 1953-07-13 | 1955-10-18 | Hoffmann La Roche | Sulfisoxazole compounds |
| US2881160A (en) * | 1955-11-30 | 1959-04-07 | Hoffmann La Roche | Bis-isoxazolyl-azobenzene-derivatives |
| US2888455A (en) * | 1956-09-04 | 1959-05-26 | Shionogi & Co | New sulfonamide and process for producing the same |
| US3482957A (en) * | 1965-11-26 | 1969-12-09 | Toyo Kotsu Ind Inc | Method for suppressing the nitrification of ammonium nitrogen in soil and composition therefor |
| US3468900A (en) * | 1966-08-24 | 1969-09-23 | Hoffman Lab Inc | Process for preparing isoxazole compounds |
| US3996356A (en) * | 1969-07-02 | 1976-12-07 | Hoffmann-La Roche Inc. | Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dodson et al. | The reaction of ketones with halogens and thiourea1 | |
| US4284786A (en) | 5-Methylisoxazole-4-carboxylic-(4-trifluoromethyl)-anilide | |
| EP0091468B1 (en) | (1-(2-benzoxazolyl)hydrazino)alkyl nitrile derivatives | |
| JPS61286376A (en) | Thiazolidine derivative, production thereof and pharmaceutical composition containing said derivative | |
| US2430094A (en) | Isoxazole derivatives of | |
| US3332942A (en) | Substituted thiadiazoles | |
| US3288787A (en) | Substituted oxazolidinones | |
| US3133912A (en) | Reaction product of amino carbohy-drates with therapeutically effective amino compounds | |
| US2332906A (en) | Process for preparation of sulphonamide derivatives | |
| JPS61502959A (en) | 4↓-(isoxazolyl)↓-thiazole↓-2↓-oxamic acid derivative | |
| US2288531A (en) | Benzenesulphonamide compounds | |
| US2289029A (en) | Arylsulphonamides of the benzene series | |
| US2524802A (en) | Hydroxybenzenesulfonamidopyridazines and preparation of same | |
| US4246272A (en) | Benzamidine derivatives | |
| US2366189A (en) | Sulpha-thiazoles | |
| US2409291A (en) | Chemotherapeutic sulfanilamide derivatives | |
| US2525321A (en) | Hydroxybenzenesulfonamidoisoxazoles and preparation of same | |
| US2404199A (en) | 2-sulphanilamido-quinoxaline | |
| US2721200A (en) | Sulfisoxazole compounds | |
| US3090788A (en) | Substituted isoxazole carboxamide compounds | |
| JPS6025963A (en) | Manufacture of 2-ketone sulfonamides | |
| US2510925A (en) | 2-sulfanilamido-5-carbamylthiazole and its production | |
| US2477537A (en) | Para-nitrobenzyl ethers of tyrosine and certain derivatives | |
| US2430051A (en) | Soluble sulfanilamide derivatives and process of preparing them | |
| US2339788A (en) | Substituted para-aminobenzene sulphonamide compound |